2 completed. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Pharma Two B Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study With P2B001 in Subjects With Early Parkinson's P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg - Parkinson Disease, Early Parkinson's Disease | Phase 3 | Completed | Pharma Two B Ltd. | 544 | 2018-01-19 | 2023-03-21 |
| Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, Placebo, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), - Parkinson's Disease | Phase 2 / Phase 3 | Completed | Pharma Two B Ltd. | 149 | 2013-12-01 | 2023-04-07 |
Pramipexole (2) · rasagiline (2)
United States (2) · Canada (1) · Germany (1) · Israel (1) · Spain (1)
Pninit Litman (1)